AVENACY REPORTS STRONG 2024 PERFORMANCE, OUTLINES 2025 STRATEGIC PRIORITIES

KUALA LUMPUR, Jan 7 (Bernama) -- Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, has provided an update on recent business highlights and financial performance for 2024 and outlined its strategic priorities for this year.

The company shared the updates ahead of its participation in the 43rd Annual J.P. Morgan Healthcare Conference from Jan 13-16, in San Francisco, California.

Avenacy’s leadership team, including Co-Founder & Chief Executive Officer, Jeff Yordon; Chief Operating Officer, Joe Mase; and Vice President of Finance, Peter Jensen, will be meeting with investors and showcasing the company’s recent accomplishments and plans for 2025.

“2024 was a breakout year for Avenacy marked by exceptional growth and tremendous progress. 2025 will be a pivotal year for the organisation, and we are confident in our ability to achieve our ambitious portfolio and broader business goals.

“As we continue to position our business for accelerated growth, we remain committed to our mission of enhancing patient care and addressing critical gaps in the United States healthcare system,” said Yordon in a statement.

In 2024, Avenacy achieved solid revenue performance in the first full year of operation, underpinned by its portfolio of 14 critical injectable medications. The company’s fiscal performance establishes a strong foundation for future growth, with expectations of continued annual sales growth and profit expansion.

The company has also built strong commercial leadership and infrastructure, establishing partnerships with major wholesalers, completing the necessary staffing and securing state licences. Avenacy's leadership team strengthened with the addition of Dr Patrick Soon-Shiong, a pharmaceutical veteran, who brings extensive experience in the commercialisation of injectable generic medications.

All of its products feature differentiated packaging and labelling to assist pharmacists and clinicians with accurate medication selection. Avenacy continues to pursue opportunities to bring products to market that improve safety and convenience, such as ready-to-use dosage forms and formulations that are easier to store.

Looking ahead to 2025, Avenacy remains on track to launch over 25 products by year-end, continue to build-out its foundational portfolio of critical acute care medications and shortage products, and secure further investment to support its long-term growth portfolio.

Avenacy raised capital in August to fund its 2025 growth, and the company is seeking additional funding to expand both its foundational and growth portfolios. As it enters its second year of operations, Avenacy is focused on sustaining its momentum and securing strategic investments for continued success.

-- BERNAMA

BITGET INTRODUCES BANK DEPOSITS WITH ZEN INTEGRATION, ENABLING ACCESS FOR ELEVEN FIAT CURRENCIES

VICTORIA, Seychelles, Jan 8 (Bernama-GLOBE NEWSWIRE) -- Bitget, the leading cryptocurrency exchange and Web3 company, is excited to announce the integration of ZEN.com, a renowned banking solution, into its fiat deposit and withdrawal channel. With this integration, Bitget users can now seamlessly deposit and withdraw funds using 11 supported fiat currencies, including PLN, CZK, DKK, AUD, CAD, NOK, SEK, CHF and HUF.

This collaboration shows Bitget’s focus on enhancing accessibility and improving the user experience, particularly in underserved European markets and major regions such as Oceania.

“Our partnership with ZEN.com aligns with our plans of making crypto trading more accessible to users worldwide. By supporting more fiat currencies than our competitors and offering instant fiat on-ramp options, we’re empowering users with convenient and innovative trading solutions," said Gracy Chen, CEO at Bitget.

Bitget’s ZEN integration offers a multitude of benefits. Users can deposit and withdraw funds in 11 fiat currencies, more than what other CEXs currently provide. With instant fiat on-ramp, users gain access to instant cash conversion to crypto via Bitget. There are no hidden charges, and zero deposit fees help users benefit from fee rebates during the promotional period.

To celebrate this partnership, Bitget and ZEN are launching an exclusive campaign, rewarding users with a 3-month ZEN PRO trial, zero deposit fees, and up to 25% rebates on fiat-to-crypto conversions.

The event runs from January 7th, 2025, 18:00 (UTC+8) to February 4th, 2025, 18:00 (UTC+8). Participants can register here by creating a ZEN account for a free 3-month PRO trial, making a fee-free deposit in supported fiat currencies, and converting fiat to crypto to earn up to 25% rebates.

For detailed instructions on how to deposit via ZEN, visit here.

About Bitget

Established in 2018, Bitget is the world's leading cryptocurrency exchange and Web3 company. Serving over 45 million users in 150+ countries and regions, the Bitget exchange is committed to helping users trade smarter with its pioneering copy trading feature and other trading solutions, while offering real-time access to Bitcoin price, Ethereum price, and other cryptocurrency prices. Formerly known as BitKeep, Bitget Wallet is a world-class multi-chain crypto wallet that offers an array of comprehensive Web3 solutions and features including wallet functionality, token swap, NFT Marketplace, DApp browser, and more.

Bitget is at the forefront of driving crypto adoption through strategic partnerships, such as its role as the Official Crypto Partner of the World's Top Football League, LALIGA, in EASTERN, SEA and LATAM markets, as well as a global partner of Turkish National athletes Buse Tosun Çavuşoğlu (Wrestling world champion), Samet Gümüş (Boxing gold medalist) and İlkin Aydın (Volleyball national team), to inspire the global community to embrace the future of cryptocurrency.

For more information, visit: Website | Twitter | Telegram | LinkedIn | Discord | Bitget Wallet

For media inquiries, please contact: media@bitget.com

Risk Warning: Digital asset prices are subject to fluctuation and may experience significant volatility. Investors are advised to only allocate funds they can afford to lose. The value of any investment may be impacted, and there is a possibility that financial objectives may not be met, nor the principal investment recovered. Independent financial advice should always be sought, and personal financial experience and standing carefully considered. Past performance is not a reliable indicator of future results. Bitget accepts no liability for any potential losses incurred. Nothing contained herein should be construed as financial advice. For further information, please refer to our Terms of Use.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/c5896ba2-052c-4cfa-8f39-e222f41ad1be

SOURCE : Bitget Limited

CARTERRA SHIPS ULTRA BIOSENSOR PLATFORM, WRAPS UP 2024 WITH DOUBLE-DIGIT GROWTH

KUALA LUMPUR, Jan 8 (Bernama) -- Carterra Inc, the world leader in enabling high-throughput biology, announced it has delivered its first Carterra Ultra biosensor platform and closed 2024 with double-digit growth and record revenues.

Announced in September 2024, the Ultra instrument provides a full complement of small and large molecule applications while reprising gold-standard surface plasmon resonance (SPR) detection, high-throughput, and the minimal sample requirements of Carterra’s systems.

Its Chief Commercial Officer, Tim Germann acknowledged the challenges in capital equipment spending over recent years.

“Even so, drug and vaccine discovery groups are focused more than ever on going faster and spending less money to bring life-saving therapies to market, that is exactly what Carterra platforms enable,” he said in a statement.

The Ultra is capable of characterising molecules as small as 100 Daltons, with early customers utilising it to study molecular glues, PROTACS, DNA-encoded libraries (DELs), kinases, membrane proteins, and ligandability.

The platform also boasts faster analysis speeds, flexible referencing, and new screening software for fragment and small molecule applications.

For the first time, investigators can conduct fragment-based lead discovery, small-molecule analysis, and large molecule protein-protein interactions, including on- and off-target measurements at industrial scale.

Leading biopharma scientists will be showcasing groundbreaking new data generated with the Carterra Ultra platform this month with presentations at SLAS2025 International Conference & Exhibition, and Drug Discovery Chemistry 2025, both to be held in San Diego, California.

These presentations will highlight the platform's impact on advancing fragment and small molecule drug discovery while also demonstrating how Ultra enables innovative workflows and accelerates discovery timelines.

-- BERNAMA

AHF CALLS ON ASEAN TO TAKE LEADERSHIP IN COMBATTING HIV/AIDS IN APAC

KUALA LUMPUR, Jan 2 (Bernama) -- AIDS Healthcare Foundation (AHF), a global non-profit provider of HIV/AIDS medical care, has urged the Association of Southeast Asian Nations (ASEAN) to lead the fight in ending AIDS as a public health threat in the Asia Pacific (APAC) region.

Having served over 400,000 clients across 10 APAC countries, AHF in a statement said it is eager to contribute its expertise to support ASEAN’s ambitious goals.

AHF President, Michael Weinstein emphasised that ASEAN's efforts could significantly impact the global fight against HIV/AIDS.

“By building partnerships with governments, civil society, and international agencies—and focusing on community-based approaches—ASEAN can demonstrate that ending AIDS as a public health threat is within reach.

“This progress would save lives, reduce healthcare costs, boost workforce productivity, and strengthen communities, while setting an example for other regions to follow,” he said.

Meanwhile, AHF Asia Bureau Chief, Dr Chhim Sarath expressed pride in the organisation’s collaborations with the majority of ASEAN countries and their civil society organisations (CSOs).

“As we welcome the New Year, we urge ASEAN and its member states to enhance collaboration and establish robust mechanisms to develop a ‘Road Map to End AIDS in the ASEAN Region’, with active engagement from CSOs like AHF,” added Dr Sarath.

AHF proposes working through platforms such as the ASEAN GO-NGOs Forum to promote collaboration, address inequalities, eliminate stigma and discrimination, and ensure access to the prevention and treatment of HIV and other sexually transmitted infections.

The non-profit organisation provides cutting-edge medicine and advocacy to over two million people in 48 countries worldwide, including the United States, Africa, Latin America/Caribbean, the Asia/Pacific Region, and Europe.

-- BERNAMA